Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Interest Expenses (2016 - 2017)

CytomX Therapeutics (CTMX) has disclosed Interest Expenses for 4 consecutive years, with $206000.0 as the latest value for Q1 2017.

  • For the quarter ending Q1 2017, Interest Expenses fell 41.64% year-over-year to $206000.0, compared with a TTM value of $206000.0 through Dec 2017, down 87.8%, and an annual FY2016 reading of $1.7 million, down 2.48% over the prior year.
  • Interest Expenses was $206000.0 for Q1 2017 at CytomX Therapeutics, down from $389000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $718000.0 in Q3 2015 and bottomed at $109000.0 in Q4 2014.
  • Average Interest Expenses over 4 years is $373600.0, with a median of $382500.0 recorded in 2015.
  • The sharpest move saw Interest Expenses surged 244.95% in 2015, then tumbled 41.64% in 2017.
  • Year by year, Interest Expenses stood at $109000.0 in 2014, then soared by 244.95% to $376000.0 in 2015, then rose by 3.46% to $389000.0 in 2016, then crashed by 47.04% to $206000.0 in 2017.
  • Business Quant data shows Interest Expenses for CTMX at $206000.0 in Q1 2017, $389000.0 in Q4 2016, and $482000.0 in Q3 2016.